中国麻风皮肤病杂志 ›› 2019, Vol. 35 ›› Issue (11): 696-700.doi: 10.12144/zgmfskin201911696

• 综述 • 上一篇    下一篇

生物制剂治疗银屑病的药物遗传学研究进展

戴华拓  任韵清   

  1. 浙江大学医学院附属第二医院皮肤科,浙江杭州，310000
  • 出版日期:2019-11-15 发布日期:2019-11-20
  • 通讯作者: 任韵清，E-mail：yqren@zju.edu.cn

Update on pharmacogenetics of biological agents in the treatment of psoriasis

DAI Huatuo, REN Yunqing   

  1. Department of Dermatology, The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou 310000, China
  • Online:2019-11-15 Published:2019-11-20
  • Contact: REN Yunqing, E-mail: yqren@zju.edu.cn

PDF (PC)

119

摘要： 研究者们发现IL-23/Th7轴在银屑病发病中具有中心地位，直接或间接靶向于此通路的生物制剂如TNF-α抑制剂、IL-12/23抑制剂、IL-17抑制剂等在治疗中重度银屑病中有明显疗效。药物遗传学通过研究药物疗效与不同个体之间基因多态性的关联，可以预测药物疗效的个体差异。生物制剂的药物遗传学研究和应用可以使银屑病的治疗更加合理及个体化，本文对生物制剂治疗银屑病的药物遗传学研究进行了综述。

关键词: 银屑病, 生物制剂, 药物遗传学

Abstract: IL-23/Th17 axis has been found to play a central role in the  pathogenesis of psoriasis. Biological agents, such as TNF-α inhibitors, IL-12/23 antagonists, IL-17 antagonists, which are directly or indirectly targeted to this pathway, are impressive in the treatment of moderate to severe psoriasis. Pharmacogenetics can predict drug efficacy between different individuals by studying the association of drug efficacy. The pharmacogenetic research and application of biological agents can make the treatment of psoriasis more reasonable and individualized. The update on pharmacogenetics of biological agents in the treatment of psoriasis is reviewed in this paper.

Key words: psoriasis, biological agents, pharmacogenetics